Furthermore, in mice, the overexpression of IL-13Rα2 counteracted the tumor growth inhibitory effect of doxorubicin, resulting in no significant difference in tumor size between the IL-13Rα2 overexpression group and the control group not treated with doxorubicin (Figure 6C). This evidence concerns the gene IL13RA2 and neoplasm.